A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Adenosine A2 Receptor Antagonists/*pharmacology ; Cocaine/*pharmacology ; Corpus Striatum/*metabolism ; Dopamine Uptake Inhibitors/*pharmacology ; Motor Activity/*drug effects ; Receptor, Adenosine A2A/*metabolism ; Receptor, Cannabinoid, CB1/*metabolism ; Synaptic Transmission/*drug effects; Animals ; Antipsychotic Agents/pharmacology ; Caffeine/pharmacology ; Central Nervous System Stimulants/pharmacology ; Cholinergic Neurons/metabolism ; Male ; Rats ; Rats, Wistar ; Sulpiride/pharmacology
    • Abstract:
      Background: Cocaine increases the level of endogenous dopamine (DA) in the striatum by blocking the DA transporter. Endogenous DA modulates glutamatergic inputs to striatal neurons and this modulation influences motor activity. Since D2 DA and A2A-adenosine receptors (A2A-Rs) have antagonistic effects on striatal neurons, drugs targeting adenosine receptors such as caffeine-like compounds, could enhance psychomotor stimulant effects of cocaine. In this study, we analyzed the electrophysiological effects of cocaine and A2A-Rs antagonists in striatal slices and the motor effects produced by this pharmacological modulation in rodents.
      Principal Findings: Concomitant administration of cocaine and A2A-Rs antagonists reduced glutamatergic synaptic transmission in striatal spiny neurons while these drugs failed to produce this effect when given in isolation. This inhibitory effect was dependent on the activation of D2-like receptors and the release of endocannabinoids since it was prevented by L-sulpiride and reduced by a CB1 receptor antagonist. Combined application of cocaine and A2A-R antagonists also reduced the firing frequency of striatal cholinergic interneurons suggesting that changes in cholinergic tone might contribute to this synaptic modulation. Finally, A2A-Rs antagonists, in the presence of a sub-threshold dose of cocaine, enhanced locomotion and, in line with the electrophysiological experiments, this enhanced activity required activation of D2-like and CB1 receptors.
      Conclusions: The present study provides a possible synaptic mechanism explaining how caffeine-like compounds could enhance psychomotor stimulant effects of cocaine.
    • References:
      J Neurosci. 2011 Feb 2;31(5):1850-62. (PMID: 21289195)
      J Neurosci. 2007 May 9;27(19):5260-4. (PMID: 17494712)
      Trends Neurosci. 1990 Jul;13(7):281-5. (PMID: 1695404)
      Nat Neurosci. 2009 Sep;12(9):1121-8. (PMID: 19668198)
      Br J Pharmacol. 2010 Jun;160(3):443-53. (PMID: 20590556)
      J Neurosci. 2005 Nov 9;25(45):10537-45. (PMID: 16280591)
      Neurology. 2003 Dec 9;61(11 Suppl 6):S19-23. (PMID: 14663004)
      Nature. 2003 Oct 30;425(6961):917-25. (PMID: 14586460)
      J Neurosci. 2010 Feb 10;30(6):2160-4. (PMID: 20147543)
      J Neurosci. 1992 Nov;12(11):4224-33. (PMID: 1359031)
      Neuropharmacology. 2007 Nov;53(6):783-9. (PMID: 17889039)
      Science. 1990 Dec 7;250(4986):1429-32. (PMID: 2147780)
      Neuron. 2000 Mar;25(3):515-32. (PMID: 10774721)
      Trends Neurosci. 1989 Oct;12(10):366-75. (PMID: 2479133)
      J Neurosci. 1999 Jul 1;19(13):5586-96. (PMID: 10377365)
      Physiol Behav. 2007 Sep 10;92(1-2):210-7. (PMID: 17572452)
      Prog Brain Res. 2008;172:347-60. (PMID: 18772041)
      Semin Cell Dev Biol. 2009 Jun;20(4):395-402. (PMID: 19560044)
      Ann N Y Acad Sci. 2001 Jun;937:93-120. (PMID: 11458542)
      Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. (PMID: 15095008)
      Curr Drug Abuse Rev. 2010 Mar;3(1):49-62. (PMID: 20088819)
      J Neurosci. 2001 Apr 15;21(8):2799-807. (PMID: 11306632)
      Brain Res. 2003 Oct 3;986(1-2):22-9. (PMID: 12965226)
      Neuron. 2006 May 4;50(3):443-52. (PMID: 16675398)
      J Comp Neurol. 1985 Feb 22;232(4):481-98. (PMID: 2579980)
      AAPS J. 2005 Oct 05;7(2):E353-60. (PMID: 16353915)
      J Neurophysiol. 2000 Jan;83(1):322-32. (PMID: 10634875)
      J Neurosci. 2008 Mar 19;28(12):2970-5. (PMID: 18354001)
      Eur J Neurosci. 2009 Oct;30(7):1269-79. (PMID: 19769590)
      Nat Neurosci. 2008 Dec;11(12):1376-7. (PMID: 18978779)
      J Neurosci. 2004 Dec 8;24(49):11070-8. (PMID: 15590923)
      J Neurosci. 2007 Jan 24;27(4):791-5. (PMID: 17251418)
      Nat Neurosci. 2006 Aug;9(8):1050-6. (PMID: 16829955)
      J Alzheimers Dis. 2010;20 Suppl 1:S35-49. (PMID: 20182056)
      Neuropsychopharmacology. 2004 Aug;29(8):1488-97. (PMID: 15100701)
      Psychopharmacology (Berl). 1997 Sep;133(2):107-20. (PMID: 9342776)
      J Neurosci. 2011 Aug 31;31(35):12513-22. (PMID: 21880913)
      J Neurosci. 1998 Oct 15;18(20):8539-49. (PMID: 9763496)
      J Neurosci. 2002 May 1;22(9):3306-11. (PMID: 11978804)
      Nat Neurosci. 2002 May;5(5):446-51. (PMID: 11976704)
      Nat Rev Neurosci. 2003 Nov;4(11):873-84. (PMID: 14595399)
      Science. 1987 Sep 4;237(4819):1219-23. (PMID: 2820058)
      Brain. 2011 Jan;134(Pt 1):110-8. (PMID: 21097493)
      Nat Neurosci. 1999 Apr;2(4):358-63. (PMID: 10204543)
      J Neurosci. 1993 Nov;13(11):4908-23. (PMID: 7693897)
      Rev Neurosci. 2008;19(2-3):113-28. (PMID: 18751519)
      Proc Natl Acad Sci U S A. 2006 May 23;103(21):8251-6. (PMID: 16698932)
      Ann Neurol. 1998 May;43(5):586-97. (PMID: 9585352)
      J Chem Neuroanat. 2006 Dec;32(2-4):101-16. (PMID: 16914290)
      Life Sci. 1990;46(9):635-45. (PMID: 2308472)
      J Neurosci. 2010 Aug 18;30(33):11043-56. (PMID: 20720111)
      Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1593-600. (PMID: 17900777)
      J Psychopharmacol. 1998;12(1):49-53. (PMID: 9584968)
      Neuropharmacology. 2009;56 Suppl 1:226-34. (PMID: 18691604)
      Prog Brain Res. 1993;99:209-26. (PMID: 8108549)
      J Neurosci. 2008 Aug 6;28(32):8040-52. (PMID: 18685029)
      Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91. (PMID: 8401595)
      Am J Psychiatry. 2005 Aug;162(8):1403-13. (PMID: 16055761)
      Trends Neurosci. 2006 Nov;29(11):647-54. (PMID: 17030429)
      Prog Neurobiol. 2007 Dec;83(5):277-92. (PMID: 17646043)
    • Accession Number:
      0 (Adenosine A2 Receptor Antagonists)
      0 (Antipsychotic Agents)
      0 (Central Nervous System Stimulants)
      0 (Dopamine Uptake Inhibitors)
      0 (Receptor, Adenosine A2A)
      0 (Receptor, Cannabinoid, CB1)
      3G6A5W338E (Caffeine)
      7MNE9M8287 (Sulpiride)
      I5Y540LHVR (Cocaine)
    • Publication Date:
      Date Created: 20120621 Date Completed: 20150212 Latest Revision: 20211021
    • Publication Date:
      20240829
    • Accession Number:
      PMC3371006
    • Accession Number:
      10.1371/journal.pone.0038312
    • Accession Number:
      22715379